Abstract
Transforming growth factor-β (TGF-β) is an important target for treating systemic sclerosis (SSc). However, our study revealed three levels of TGF-β1 expression in SSc patients, indicating that inhibiting TGF-β is not sufficient to treat SSc. A previous clinical trial also displayed disappointing results. Thus, our study attempted to search for a potential novel approach. Ingenuity Pathway Analysis (IPA) indicated that the SSc pathological pathways were closely associated with store-operated Ca2+ entry (SOCE)-regulated signals, and SOCE activity was found to be increased in SSc fibroblasts. Further treatment of SSc fibroblasts with SOCE inhibitors, 2APB, and associated calcium channel inhibitors SKF96365, and indomethacin, showed that the SOCE inhibitors selectively decreased fibrosis markers and altered the cell morphology. Consequently, SOCE inhibitors, especially 2APB and indomethacin, caused the dedifferentiation of SSc fibroblasts via cytoskeleton remodeling and altered collagen secretion and restored the cell mobility. We further explained SSc pathogenesis as fibroblast differentiation with SOCE. Treatment with exogenous factors, gelatin-1, FAM20A and human albumin, which were identified from the conditioned medium of SSc fibroblasts, was important for regulating the differentiation of fibroblasts with higher levels of SOCE and α-SMA. Conclusively, to treat SSc, blockage of the increased SOCE activity in SSc induces the dedifferentiation of SSc fibroblasts and simultaneously changes the extracellular matrix (ECM) structure to limit SSc pathogenesis.
Highlights
Systemic sclerosis (SSc), a severe multisystem autoimmune disease, is characterized by progressive fibrosis that can influence all organs in the body [1]
In this study we attempted to look for a potential novel approach that would be effective for SSc therapy
TGF-β1 is a crucial target in treating SSc, skin biopsies from SSc patients revealed that the TGF-β1 level differed from that of the paired normal skin biopsies
Summary
Systemic sclerosis (SSc), a severe multisystem autoimmune disease, is characterized by progressive fibrosis that can influence all organs in the body [1]. Previous study indicated the majority of SSc deaths involve pulmonary fibrosis, pulmonary arterial hypertension and cardiac causes [2].the low efficacy of immunosuppressive treatments suggest a complicated pathogenesis of fibrosis and unknown mechanisms in SSc. For treating fibrotic diseases, especially SSc, several recent studies focused on transforming growth factor-β (TGF-β) as a potential target for anti-fibrotic therapy because TGF-β is a crucial mediator of fibrosis[3]. The excess TGF-β activity in SSc contributes to overproduction of collagen, a component of the extracellular matrix (ECM) [3]. TGF-β or/and TGF-β-induced collagen overproduction can cause the differentiation of fibroblasts to myofibroblasts, and myofibroblasts accelerate fibrosis by changing ECM collagen fibers [4]. There is still no efficient approach for treating fibrotic diseases, especially SSc
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.